Moura Mariana Del Grossi, Lopes Luis Phillipe Nagem, de Oliveira Jardel Corrêa, Neiva Lais, Fulone Izabela, Mazzei Lauren Giustti, Santos Danielle Maria de Souza Serio Dos, Lopes Luciane Cruz
Pharmaceutical Sciences Graduate Course, University of Sorocaba, Sorocaba, Brazil.
Institute of Social Medicine, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
BMJ Open. 2025 Jul 6;15(7):e098258. doi: 10.1136/bmjopen-2024-098258.
To identify and contextualise evidence-based strategies for implementing deprescribing practices at different levels of healthcare in Brazil, through the development of an evidence brief for policy that includes stakeholder deliberation and considers barriers, facilitators and equity aspects.
This protocol outlines the development of an evidence brief for policy using a mixed-methods design. It involves synthesising evidence for health policies by integrating global research and local evidence through three stages: stakeholder exchange, evidence brief development and external endorsement. The Supporting Policy-Relevant Reviews and Trials tools for evidence-informed health policies will guide both the synthesis of strategies and the facilitation of deliberative dialogues. The synthesis will encompass evidence from systematic reviews and meta-analysis on deprescribing strategies across healthcare levels, focusing on effectiveness, harms, costs, perceptions, barriers, facilitators and equity. Studies proposing strategies not yet implemented will be excluded. Study selection and data extraction will be conducted independently and in duplicate. The methodological quality of included studies will be assessed using the A Measurement Tool for Assessing the Methodological Quality of Systematic Reviews-2 criteria. Synthesised evidence will be used to develop evidence-based strategies, which will then be presented in deliberative dialogues for endorsement by stakeholders and adaptation to the Brazilian context. Endorsement rates will be classified as high, moderate or low based on predefined criteria.
This study was approved by the University of Sorocaba Research Ethics Committee (certificate 82098324.7.0000.5500). Informed consent will be obtained from all participants. Findings will be disseminated through peer-reviewed publications and conference presentations.
CRD42024548845.
通过制定一份政策证据摘要，其中包括利益相关者的审议，并考虑障碍、促进因素和公平性方面，来确定并将基于证据的策略置于巴西不同医疗保健层面的去处方实践背景中。
本方案概述了使用混合方法设计制定政策证据摘要的过程。它涉及通过三个阶段整合全球研究和本地证据来综合卫生政策证据：利益相关者交流、证据摘要制定和外部认可。支持循证卫生政策的相关综述和试验工具将指导策略的综合以及审议性对话的促进。综合将涵盖来自系统评价和荟萃分析的关于不同医疗保健层面去处方策略的证据，重点关注有效性、危害、成本、认知、障碍、促进因素和公平性。提出尚未实施的策略的研究将被排除。研究选择和数据提取将独立进行并重复操作。将使用系统评价方法学质量评估测量工具-2标准评估纳入研究的方法学质量。综合证据将用于制定基于证据的策略，然后在审议性对话中呈现，以供利益相关者认可并根据巴西背景进行调整。认可率将根据预定义标准分为高、中或低。
本研究已获得索罗卡巴大学研究伦理委员会批准（证书82098324.7.0000.5500）。将从所有参与者处获得知情同意。研究结果将通过同行评审出版物和会议报告进行传播。
PROSPERO注册号：CRD42024548845。
